Didier Saurigny
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).
Journal: BMJ open
Published: March 05, 2025
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Journal: Annals of the rheumatic diseases
Published: May 25, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Journal: Annals of the rheumatic diseases
Published: May 18, 2023
Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' reply.
Journal: The Lancet. Rheumatology
Published: March 23, 2021
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study.
Journal: The Lancet. Rheumatology
Published: December 20, 2019
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Journal: The Lancet. Rheumatology
Published: December 20, 2019
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Journal: Arthritis research & therapy
Published: December 12, 2018
Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: August 02, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026